UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | May 14, 2021 12:00 P.M. |
Form: | S-4 | ||||||
| |||||||
|
UNITED STATES | |
SECURITIES AND EXCHANGE COMMISSION | |
Washington, D.C. 20549 | |
Notice of Effectiveness | |
Effectiveness Date: | May 14, 2021 12:00 P.M. |
Form: | S-4 | ||||||
| |||||||
|
SC 13G/A - Intec Pharma Ltd. (0001638381) (Subject)
15-12B - Intec Pharma Ltd. (0001638381) (Filer)
25-NSE - Intec Pharma Ltd. (0001638381) (Subject)
425 - Intec Pharma Ltd. (0001638381) (Subject)
NEW YORK, Aug. 3, 2021 /PRNewswire/ -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company," and formerly, Intec Parent, Inc.) today announced the closing of its previously announced merger with Decoy Biosystems, Inc. ("Decoy") and the completion of a $30 million private placement in accordance with the merger agreement. In addition, the Company announced a corporate name change to Indaptus Therapeutics, as it better reflects the Company's therapeutic focus. Indaptus is expected to begin trading on the Nasdaq Capital Market at the open of trading on August 4, 2021, under the ticker symbol "INDP" and a new CUSIP number (45339J 105). The previous ticker symbol was "NTEC" (NA
JERUSALEM, Aug. 3, 2021 /PRNewswire/ -- Intec Parent, Inc. (NASDAQ:NTEC) ("Intec Parent" or the "Company"), today announced that the pending and previously announced reverse merger (the "Decoy Merger") with Decoy Biosystems, Inc. ("Decoy") is currently expected to close after market hours today, Tuesday, August 3, 2021, subject to satisfaction or waiver of all closing conditions. Immediately following the closing, the combined company will be renamed "Indaptus Therapeutics, Inc.", and is expected to begin trading on The Nasdaq Capital Market under the new ticker symbol "INDP" upon the commencement of trading on Wednesday, August 4, 2021. In connection with the Decoy Merger and the previously
JERUSALEM, July 26, 2021 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ:NTEC) ("Intec Israel" or the "Company"), today announced that its wholly-owned subsidiary, Intec Parent, Inc. ("Intec US"), entered into a securities purchase agreement with a single, healthcare-focused institutional investor to raise $30 million in a private placement. The private placement is being consummated to satisfy one of the closing conditions of the previously announced reverse merger with Decoy Biosystems, Inc. (the "Decoy Merger"). In connection with the Decoy Merger, Intec Israel plans to effect a 1-for-4 reverse share split of its outstanding ordinary shares for the purpose of meeting Nasdaq's initial listing re
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and recreational. Key states driving this surge include New York, New Jersey and potentially Florida and Ohio, Bingham says. Influence Of DEA Rescheduling Following the DEA's decision to reclassify cannabis to Schedule III, Bingham predicts this will open up new avenues for medical research and investment. "We expect major medical discoveries within five years," he stated, highlighting the potential for new pharm